Patents Assigned to The Salk Institute for Biological Studies
  • Publication number: 20210220417
    Abstract: Recombinant herpes simplex virus (HSV)-1 capable of selectively replicating in alternative lengthening of telomeres (ALT)-dependent tumor cells are described. The recombinant HSV-1 are ICP0-deficient, such as by complete deletion of the ICP0 gene, or mutation of the ICP0 gene sufficient to diminish or eliminate E3 ubiquitin ligase activity of ICP0. In some cases, the recombinant HSV-1 further include additional gene deletions or mutations, such as those that render the virus glycoprotein C (gC) deficient, or include a heterologous gene, such as a gene encoding an immunostimulatory molecule. Methods of treating ALT-dependent cancer, and methods of selectively killing ALT-dependent tumor cells are also described.
    Type: Application
    Filed: November 2, 2020
    Publication date: July 22, 2021
    Applicant: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Jason DeHart
  • Publication number: 20210213306
    Abstract: The invention provides compositions featuring TRP-4 polypeptides and polynucleotides, methods for expressing such polypeptides and polynucleotides in a cell type of interest, and methods for inducing the activation of the TRP-4 polypeptide in neurons and other cell types using ultrasound.
    Type: Application
    Filed: September 23, 2020
    Publication date: July 15, 2021
    Applicant: Salk Institute for Biological Studies
    Inventors: Sreekanth H. Chalasani, Stuart Ibsen
  • Patent number: 11032225
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: June 8, 2021
    Assignee: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Patent number: 11032224
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: June 8, 2021
    Assignee: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Patent number: 11025574
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: June 1, 2021
    Assignee: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Patent number: 11013711
    Abstract: Provided herein are methods for treating type 1 diabetes and its sequelae (e.g., cardiovascular, renal or neurologic diseases for which type 1 diabetes is a risk factor) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a fatty acid ester of a hydroxy fatty acid (FAHFA), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: May 25, 2021
    Assignees: Beth Israel Deaconess Medical Center, Inc., Salk Institute for Biological Studies, President and Fellows of Harvard College
    Inventors: Barbara B. Kahn, Alan Saghatelian, Ismail Syed
  • Publication number: 20210147365
    Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Application
    Filed: September 1, 2020
    Publication date: May 20, 2021
    Applicants: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F.W. Keana, Christopher Liddle
  • Patent number: 11005799
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: May 11, 2021
    Assignee: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Publication number: 20210102206
    Abstract: Provided are modified guide RNAs (gRNAs), including dead guide RNAs (dgRNAs) with increased GC content and/or decreased repetitive content, as well as compositions and kits including such dgRNAs, which can be used in a targeted gene activation system, for example to increase expression of a gene to treat a disease in vivo. Such methods increase targeted gene expression, without creating DNA double strand breaks (DSBs).
    Type: Application
    Filed: November 25, 2020
    Publication date: April 8, 2021
    Applicant: Salk Institute for Biological Studies
    Inventors: Hsin-Kai Liao, Fumiyuki Hatanaka, Juan Carlos Izpisua Belmonte
  • Patent number: 10931613
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: February 23, 2021
    Assignee: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Patent number: 10920199
    Abstract: The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency. In particular embodiments the invention is predicated upon increased expression of an estrogen related receptor and changes in the oxidative and glycolytic pathways.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: February 16, 2021
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Ronald Evans, Michael Downes, Yasuyuki Kida, Teruhisa Kawamura, Zong Wei, Ruth T. Yu, Annette R. Atkins
  • Patent number: 10912800
    Abstract: The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: February 9, 2021
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Ronald M. Evans, Eiji Yoshihara, Michael R. Downes, Ruth T. Yu, Annette R. Atkins
  • Patent number: 10913952
    Abstract: This disclosure provides methods of downregulating or eliminating gene expression of one or more Dynamic Influencer of Gene expression (DIG) and/or one or more DIG-like (DIL) sequences in plants and plant cells, as well as constructs and compositions useful in such methods. Such recombinant plants can have decreased abscisic acid (ABA) sensitivity, decreased salt sensitivity, or both.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: February 9, 2021
    Assignee: Salk Institute for Biological Studies
    Inventors: Joseph R. Ecker, Liang Song
  • Publication number: 20210032303
    Abstract: The present disclosure provides FGF1 mutant proteins, which selectively bind to/activate FGFR1b. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed FGF1 mutants to reduce blood glucose in a mammal and treat a metabolic disorder are provided.
    Type: Application
    Filed: July 15, 2020
    Publication date: February 4, 2021
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sihao Liu, Ruth T. Yu
  • Patent number: 10906885
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: February 2, 2021
    Assignees: Mitobridge, Inc., The Salk Institute for Biological Studies
    Inventors: Michael Downes, Ronald M. Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
  • Publication number: 20210024587
    Abstract: Tumor-selective recombinant adenoviruses that possess deletions or modifications in the E3 region are described. Recombinant adenoviruses that express adenovirus death protein (ADP) but have a deletion of at least three of the remaining six E3 genes exhibit enhanced virus replication. The recombinant adenoviruses further include additional modifications to allow selective replication in tumor cells and to detarget viruses from the liver. Use of the recombinant adenoviruses for cancer treatment is described.
    Type: Application
    Filed: October 9, 2020
    Publication date: January 28, 2021
    Applicant: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Michael Lyman, William Partlo, Shigeki Miyake-Stoner
  • Patent number: 10891313
    Abstract: Methods, devices, and systems are disclosed for producing cognitive and/or sensory profiles. In one aspect, a method to provide a cognitive or sensory assessment of a subject includes selecting a profile category from among a cognitive performance profile, a sensory performance profile, and a cognitive and sensory performance profile, presenting a sequence of stimuli to a subject, the sequence of stimuli based on the selected profile category, acquiring physiological signals of the subject before, during, and after the presenting the sequence of stimuli to produce physiological data, and processing the physiological data to generate an information set including one or more quantitative values associated with the selected profile category.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: January 12, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Todd Prentice Coleman, Rui Ma, Sanggyun Kim, Cheolsoo Park, Ricardo Gil Da Costa, Raynard Fung, Diego Mesa
  • Patent number: 10864217
    Abstract: Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV).
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: December 15, 2020
    Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Lars Pache, Sumit K. Chanda, Mitchell Dennis Vamos, Nicholas David Peter Cosford, Peter Teriete, John Marlett, Arturo Diaz, John A. T. Young
  • Publication number: 20200351232
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Application
    Filed: June 3, 2020
    Publication date: November 5, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Publication number: 20200351231
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Application
    Filed: June 3, 2020
    Publication date: November 5, 2020
    Applicant: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann